Koers Cerulean Pharma Inc Nasdaq
Aandelen
US15708Q1058
Biotechnologie & Medisch Onderzoek
Omzet 2024 * | 15,62 mln. 14,42 mln. | Omzet 2025 * | 30,24 mln. 27,92 mln. | Marktkapitalisatie | 31,68 mln. 29,25 mln. |
---|---|---|---|---|---|
Nettowinst (verlies) 2024 * | -17 mln. -15,7 mln. | Nettowinst (verlies) 2025 * | -9 mln. -8,31 mln. | EV/omzet 2024 * | 2,03 x |
Nettoliquiditeiten 2024 * | - 0 | Nettoliquiditeiten 2025 * | - 0 | EV/omzet 2025 * | 1,05 x |
K/w-verhouding 2024 * |
-1,97
x | K/w-verhouding 2025 * |
-3,78
x | Werknemers | - |
Dividendrendement 2024 * |
-
| Dividendrendement 2025 * |
-
| Vrij verhandelbaar | 98,35% |
Recentste transcriptie over Cerulean Pharma Inc
Managers | Titel | Leeftijd | Van |
---|---|---|---|
Sabrina Johnson
FOU | Founder | 57 | 01-01-15 |
Annie Thurman
CTO | Chief Tech/Sci/R&D Officer | - | 01-01-22 |
Jessica Hatheway
CTO | Chief Tech/Sci/R&D Officer | - | 01-01-22 |
Besturend | Titel | Leeftijd | Van |
---|---|---|---|
Robin Steele
BRD | Director/Board Member | 68 | 01-01-15 |
Cheryl Blanchard
BRD | Director/Board Member | 59 | 20-11-19 |
Chairman | 76 | 01-01-14 |
Vaira. 1 jan. | Kapi. | |
---|---|---|
+29,03% | 49,18 mld. | |
-0,10% | 42,11 mld. | |
+47,19% | 40,37 mld. | |
-5,26% | 28,85 mld. | |
+11,48% | 26,09 mld. | |
-22,74% | 18,71 mld. | |
+9,06% | 13,26 mld. | |
+30,01% | 12,32 mld. | |
-1,51% | 11,99 mld. |